Business
PharmaCielo Receives Purchase Order for API from Brazilian Pharmaceutical Company - Represents Third Customer in the Country
PharmaCielo Receives Purchase Order for API from Brazilian Pharmaceutical Company - Represents Th...
About this update from Pharmacielo Ltd.
[{"type":"text","content":"\n \n \n \n PharmaCielo Receives Purchase Order for API from Brazilian Pharmaceutical Company - Represents Third Customer in the Country\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n PharmaCielo has received a purchase order for CBD Isolate as an API, which will be used by a large pharmaceutical company in\n \n Brazil\n \n (the \"Customer\"), for final testing.\n \n \n The Customer has already qualified PharmaCielo as a supplier of API – the Company expects to begin shipping product on a commercial basis to the Customer by Q4 2023.\n \n \n \n \n \n TORONTO\n \n and RIONEGRO, Colombia\n \n ,\n \n \n Feb. 8, 2023\n \n \n /CNW/ - PharmaCielo Ltd. (\"PharmaCielo\" or the \"Company\") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of\n \n Colombia's\n \n premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. (\"Holdings\"), today announced that it has received a purchase order for CBD Isolate as an API from a large Brazilian pharmaceutical company. The Customer is in the final stages of testing PharmaCielo's API in order to register PharmaCielo as its supplier. The Company anticipates that testing will be complete in Q3 of 2023, with commercial shipments to begin in by Q4 2023.\n \n \n \n \n \n \n \n \n \n \n \n Bill Petron\n \n \n ,\n \n CEO of PharmaCielo\n \n , said, \"With a population of over 210 million people,\n \n Brazil\n \n is a very important and growing market for PharmaCielo. Today's announcement represents further consolidation of our position in the country. Last week we announced that we had received our first commercial purchase order from\n \n Ease Labs Pharma\n \n , and in mid-2022 we signed a\n \n sales agreement\n \n with one of the largest Phyto-therapeutic companies in the Brazilian market. We see significant potential to expand sales volume within each of these relationships, as well as to broaden the scope to include additional APIs, such as broad spectrum, as the market continues to grow. While the equity market environment rem...